Effects of Cannabinoids on Anxiety in Mice and Rats
Author Information
Author(s): József Haller, F. Mátyás, K. Soproni, B. Varga, B. Barsy, B. Németh, É. Mikics, T. F. Freund, N. Hájos
Primary Institution: Institute of Experimental Medicine, Department of Behavioral Neurobiology
Hypothesis
Discrepant findings in anxiety-related effects of cannabinoids result from species differences in the responsiveness of GABAergic and glutamatergic neurotransmission.
Conclusion
Cannabinoid agonist WIN-55,212 reduced anxiety in mice but increased anxiety in rats, with the antagonist AM-251 having opposite effects in the two species.
Supporting Evidence
- In mice, WIN-55,212 decreased anxiety while AM-251 increased it.
- In rats, WIN-55,212 increased anxiety, and AM-251 potentiated this effect.
- IPSCs were more sensitive to WIN-55,212 in mice than in rats.
- The study suggests that cannabinoid effects on anxiety depend on the balance of GABAergic and glutamatergic neurotransmission.
Takeaway
Cannabinoids can make mice less anxious but can make rats more anxious, depending on how their brains respond to these substances.
Methodology
The study compared the effects of cannabinoid agonist WIN-55,212 and antagonist AM-251 on anxiety in CD1 mice and Wistar rats using behavioral tests and electrophysiological recordings.
Potential Biases
Potential bias due to the specific strains of animals used and the experimental conditions that may not generalize to other contexts.
Limitations
The study primarily focused on two specific strains of mice and rats, which may not represent all species or strains.
Participant Demographics
CD1 mice and Wistar rats, approximately two months old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website